Based on the analysis of Intelligent Bio's profitability, liquidity, and operating efficiency, Intelligent Bio Solutions is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March. At this time, Intelligent Bio's Non Currrent Assets Other are comparatively stable compared to the past year. Net Invested Capital is likely to gain to about 10.7 M in 2025, whereas Short and Long Term Debt Total is likely to drop slightly above 745.1 K in 2025. Key indicators impacting Intelligent Bio's financial strength include:
The financial analysis of Intelligent Bio is a critical element in measuring its lifeblood. Investors should not minimize Intelligent Bio's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(9.6 Million)
Intelligent
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Average Inventory
Research And Ddevelopement To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Sales Outstanding
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Investments
Stock Based Compensation
Total Cashflows From Investing Activities
Other Non Cash Items
Change To Account Receivables
Change To Operating Activities
Change To Netincome
Change To Liabilities
Change To Inventory
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Accounts Payable
Cash
Cash And Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Common Stock
Net Receivables
Common Stock Shares Outstanding
Inventory
Net Tangible Assets
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Net Invested Capital
Short Long Term Debt
Capital Stock
Net Working Capital
Other Liab
Property Plant And Equipment Net
Current Deferred Revenue
Property Plant And Equipment Gross
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Net Interest Income
Interest Income
Total Revenue
Net Income From Continuing Ops
Net Income Applicable To Common Shares
Minority Interest
Gross Profit
Cost Of Revenue
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Intelligent Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Intelligent Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in Intelligent Bio's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Intelligent Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Intelligent Bio Solutions. Check Intelligent Bio's Beneish M Score to see the likelihood of Intelligent Bio's management manipulating its earnings.
Intelligent Bio Stock Summary
Intelligent Bio competes with Futuretech, Artisan Partners, Eastman Chemical, Avient Corp, and Ameriprise Financial. GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd. Intelligent Bio operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.
The reason investors look at the income statement is to determine what Intelligent Bio's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Intelligent Bio's current stock value. Our valuation model uses many indicators to compare Intelligent Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Intelligent Bio competition to find correlations between indicators driving Intelligent Bio's intrinsic value. More Info.
Intelligent Bio Solutions is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . At this time, Intelligent Bio's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Intelligent Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Intelligent Bio Solutions Systematic Risk
Intelligent Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Intelligent Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Intelligent Bio Solutions correlated with the market. If Beta is less than 0 Intelligent Bio generally moves in the opposite direction as compared to the market. If Intelligent Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Intelligent Bio Solutions is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Intelligent Bio is generally in the same direction as the market. If Beta > 1 Intelligent Bio moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Intelligent Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Intelligent Bio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Intelligent Bio growth as a starting point in their analysis.
Intelligent Bio January 31, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Intelligent Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Intelligent Bio Solutions. We use our internally-developed statistical techniques to arrive at the intrinsic value of Intelligent Bio Solutions based on widely used predictive technical indicators. In general, we focus on analyzing Intelligent Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Intelligent Bio's daily price indicators and compare them against related drivers.
When running Intelligent Bio's price analysis, check to measure Intelligent Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intelligent Bio is operating at the current time. Most of Intelligent Bio's value examination focuses on studying past and present price action to predict the probability of Intelligent Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intelligent Bio's price. Additionally, you may evaluate how the addition of Intelligent Bio to your portfolios can decrease your overall portfolio volatility.